Advanced searches left 3/3

Cefepime - PubAg

Summarized by Plex Scholar
Last Updated: 16 October 2021

* If you want to update the article please login/register

Cefepime/tazobactam compared with other tazobactam combinations against problem Gram-negative bacteria

On this basis, Wockhardt are developing cefepime/tazobactam as a 2 +2 g q8h combination with a 90-min infusion. The task of cc cefepime/tazobactam was examined, with various other tazobactam combinations as comparators, against 1632 Enterobacterales, 745 Pseudomonas aeruginosa and 450 other non-fermenters, as sent to the UK National Reference Laboratory. At 8 +8 mg/L, task encompassed > 90% of Enterobacterales with OXA-48 and KPC carbapenemases, although the MICs for KPC producers belonging to the international Klebsiella pneumoniae ST258 lineage were higher; metallo-β-lactamase manufacturers remained immune. Cefepime/tazobactam was much less active than ceftolozane/tazobactam versus Pseudomonas aeruginosa with AmpC de-repression or high-level efflux however attained larger antipseudomonal insurance coverage than piperacillin/tazobactam. Task against various other non-fermenters was species-specific. In general, cefepime/tazobactam had a spectrum exceeding those of piperacillin/tazobactam and ceftolozane/tazobactam and looking like or surpassing that of carbapenems.

Source link: https://pubag.nal.usda.gov/catalog/7307454


Clinical impact of cefepime breakpoint in patients with carbapenem-resistant Klebsiella pneumoniae bacteraemia

The application of cefepime breakpoint for carbapenem-resistant Klebsiella pneumoniae bacteraemia has not been discovered. Adult situations of monomicrobial bloodstream infection caused by cefepime-susceptible [minimal repressive concentration ≤ 8 mg/L] K. pneumoniae isolates with carbapenem resistance in between 2010 and 2015 were assessed. Patients treated with cefepime were contrasted with those dealt with by various other active agents using a tendency score-matched evaluation to assess healing efficiency. Based on current breakpoints for Enterobacterales, cefepime therapy was not related to a damaging outcome for CRKP BSI with MIC-based dosing strategies.

Source link: https://pubag.nal.usda.gov/catalog/7194708


Heteroresistance to cefepime in Pseudomonas aeruginosa bacteraemia

The primary goal of this research study was to check out the molecular epidemiology, mechanisms and threat factors for cefepime-heteroresistant P. aeruginosa bacteraemia over about 6 years in Southwest China. A high prevalence of heteroresistance to cefepime was observed during the research study period, and these FEP-HR isolates were not clonally related.

Source link: https://pubag.nal.usda.gov/catalog/6749145


Correlation between Acinetobacter baumannii Resistance and Hospital Use of Meropenem, Cefepime, and Ciprofloxacin: Time Series Analysis and Dynamic Regression Models

The aim of this research study was to assess the use of extensively recommended antimicrobials and the respective resistance rates of A. baumannii, and to discover the relationship in between antimicrobial use and the emergence of A. baumannii resistance in a tertiary care medical facility. Temporal connections in between meropenem, ciprofloxacin, and cefepime use and the corresponding rates of A. baumannii resistance were recorded. The results of ARIMA designs showed statistically substantial correlation in between meropenem use and the detection rate of meropenem-resistant A. baumannii with a lag of 2 months.

Source link: https://pubag.nal.usda.gov/catalog/7352498


Potent inhibitory activity of taniborbactam towards NDM-1 and NDM-1Q119X mutants, and in vitro activity of cefepime/taniborbactam against MBLs producing Enterobacterales

The phenotypic account was assessed in both Enterobacterales clinical isolates and engineered Escherichia coli BL21 strains by standard brew microdilution treatments according to the Clinical and Laboratory Standards Institute. Results: Taniborbactam at a dealt with focus of 4 mg/L had the ability to bring back task of cefepime in 24 of 26 Enterobacterales scientific isolates harbouring metallo-β-lactamases with MIC ₅₀/ MIC ₉₀ values of 14 mg/L. Taniborbactam was not able to recover sensitivity to cefepime in two IMP variations creating medical isolates. Conclusion: The restraint degree of NDM enzymes given by taniborbactam shields the antibacterial task of cefepime from this essential metallo-β-lactamase.

Source link: https://pubag.nal.usda.gov/catalog/7185898


Pharmacodynamic evaluation of meropenem, cefepime, or aztreonam combined with a novel β-lactamase inhibitor, nacubactam, against carbapenem-resistant and/or carbapenemase-producing Klebsiella pneumoniae and Escherichia coli using a murine thigh-infection model

Efficiency was established by the modification in microbial quantity. The results of the in vitro research study revealed the minimum repressive focus of the combination of NAC with either MEM, FEP, or ATM in a 1:1 ratio were 2 to > 128-fold reduced than those of MEM, FEP, or ATM alone versus CRE+ isolates. On top of that, combinations of β-lactams and NAC carried out in the murine thigh-infection design revealed better efficacy against CRE+/ CPE+, CRE+/ CPE-, and CRE-/ CPE+ isolates nurturing numerous β-lactamase genes compared to MEM, FEP, ATM, and NAC alone. MEM, FEP, or ATM in combination with NAC showed potent in vivo antimicrobial activity in a murine thigh-infection design triggered by K. pneumoniae and E. coli, consisting of CRE and/or CPE isolates. These searchings for indicate that these combinations of β-lactams and NAC are prospective candidates for the treatment of CRE and/or CPE infections.

Source link: https://pubag.nal.usda.gov/catalog/7328790


Preparation of metal-organic framework based carbon materials and its application to adsorptive removal of cefepime from aqueous solution

Metal-organic framework based carbon material UC-X was prepared by design template technique, and adopted to get rid of cephalosporins from liquid remedy. According to FTIR range, with the steady increase of sodium laurate, the useful groups like carbon monoxide increased, which advertised the adsorption ability of cefepime in UC-X materials from 42. 52 to 84. 23 mg ⋅ g ⁻¹. The adsorption procedure adapted the mixed-order kinetic design, and the mistake of equilibrium adsorption ability between model suitable and real experiments is not even more than 1 %. The total outcomes of adsorption isotherm design and thermodynamic evaluation demonstrated that Redlich-Peterson isothermal model could describe the adsorption process much better.

Source link: https://pubag.nal.usda.gov/catalog/6835915


In Vitro Synergistic Effect and Mutant Prevention Concentrations of Cefepime Alone or in Combination with Sulbactam Against OXA-48-positive Klebsiella pneumoniae Isolates

Forty OXA-48-producing K. pneumoniae pressures were checked out for their Minimum repressive focus for carbapenems, cefepime, and cefepime + sulbactam by brew microdilution approach. Additionally, the mutant prevention focus s of cefepime alone or in combination with sulbactam was determined. Likewise, the in vitro collaborating task of cefepime + sulbactam combination was identified by TKC. Cefepime + sulbactam MIC variety was reduced than those for cefepime alone versus all the studied isolates. Additionally, cefepime + sulbactam combination presented reduced MPC worths than cefepime alone. The collaborating interactions of cefepime + sulbactam were achieved against researched pressures at 24 h. No enmity was observed against researched K. pneumoniae stress. The searchings for of this study presented that cefepime + sulbactam combination had collaborating or additive impact against OXA-48-producing K. pneumoniae strains. Additional examinations might be helpful for comprehending the effectiveness of cefepime + sulbactam combinations for OXA-48-positive carbapenem-resistant K. pneumoniae isolates.

Source link: https://pubag.nal.usda.gov/catalog/7066667


In vitro efficacy of imipenem-relebactam and cefepime-AAI101 against a global collection of ESBL-positive and carbapenemase-producing Enterobacteriaceae

The inhibition tasks of REL, AAI and the comparators avibactam and tazobactam, against separated recombinant β-lactamases covering reps from all 4 Ambler courses of β-lactamases, were evaluated using a fluorescence-based assay. Using recombinant healthy proteins, all 4 preventions were highly active versus the tested class A serine β-lactamases. REL and AVI showed modest task versus the Class C AmpC from Pseudomonas aeruginosa and the Class D OXA-10/ -48 SBLs, yet outmatched tazobactam and AAI. In the visibility of REL and IPM, however not AAI, susceptibility raised against Klebsiella pnuemoniae carbapenemase -positive and OXA-48-positive isolates. Both aztreonam-AVI and ceftolozane-tazobactam were more efficient than IPM-REL. In all the examined combinations, AAI was a more effective inhibitor of course A β-lactamases than the recognized inhibitors. The results cause the proposal of alternative combination therapies including REL and AAI to potentiate using β-lactams versus scientific Gram-negative isolates sharing a variety of lactamases.

Source link: https://pubag.nal.usda.gov/catalog/6846872


Evaluation of the in vitro activity of WCK 5222 (cefepime/zidebactam) and currently available combination therapies against single- and double-carbapenemase producing Enterobacteriaceae: Expanding the zone of hope

Cefepime/zidebactam is a β-lactam/ β-lactam booster antibiotic made to preserve in vitro task against Enterobacteriaceae that all at once create metallo-β-lactamase and serine-β-lactamase. We examined Enterobacteriaceae that revealed MBL and ≥ 1 SBL using gradient diffusion strip methods to figure out the minimum repressive concentration of WCK 5222 and contrast the in vitro strength of CZA+ATM vs. M/V+ATM. Task of CZA+ATM vs. M/V+ATM was contrasted using the zone of hope product, quantitated by increasing the length of inhibited growth nearby to each GDS from the factor of junction. The median ZOH item for CZA+ATM and M/V+ATM was 75. 4 and 23. 5, specifically. In strains with one carbapenemase, the average ZOH products were not statistically different, yet in pressures with an OXA-type carbapenemase, the typical item for CZA+ATM and M/V+ATM was 78. 1 and 20. 7, specifically. Thus, CZA+ATM may supply improved insurance coverage over M/V+ATM of Enterobacteriaceae co-expressing MBL and SBL.

Source link: https://pubag.nal.usda.gov/catalog/6797034

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions